DGAP-News

Evotec to present at two upcoming IR conferences (USA)

DGAP-News: Evotec AG / Key word(s): Conference
Evotec to present at two upcoming IR conferences (USA)

28.04.2016 / 10:50
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Hamburg, Germany - 28 April 2016: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner
Lanthaler, will present at two upcoming Investor Relations conferences.

Deutsche Bank 41st Annual Health Care Conference, The InterContinental
Hotel, Boston, MA, USA

Date: Thursday, 05 May 2016, 08.40 am EDT
(02.40 pm CEST)
Venue: The InterContinental Hotel, Boston, MA, USA
Presenter: Dr Werner Lanthaler,
Chief Executive Officer of Evotec AG

Berenberg European Conference USA 2016, Tarrytown House Estate, Tarrytown,
NY, USA

Date: Tuesday, 24 May 2016, 11.45 am EDT (05.45 pm CEST)
Venue: Tarrytown House Estate, Tarrytown, NY, USA
Presenter: Dr Werner Lanthaler,
Chief Executive Officer of Evotec AG


ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute).The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes,
with Pfizer in the field of tissue fibrosis and with Second Genome in the
field of inflammatory diseases. For additional information please go to
www.evotec.com.


FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.


Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [e-mail]


---------------------------------------------------------------------------

28.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX


End of News DGAP News Service
---------------------------------------------------------------------------

458629 28.04.2016